Filing Flows › Regenxbio (RGNX) › Recalls, complaints & regulation
Regenxbio (RGNX): clinical trials
Regenxbio (RGNX) beyond its filings: 7 active clinical trials.
Regenxbio's latest quarter
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Regenxbio have?
7 active studies on ClinicalTrials.gov, 3 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.